Please login to the form below

Not currently logged in


This page shows the latest Steglatro news and features for those working in and with pharma, biotech and healthcare.

NICE recommends MSD’s diabetes drug Steglatro

NICE recommends MSD’s diabetes drug Steglatro

NICE has cleared MSD’s type 2 diabetes treatment Steglatro for routine NHS use in combination with metformin, or as a monotherapy for those who are intolerant to the anti-diabetic ... MSD is hoping Steglatro can take market share from other more

Latest news

  • The year of the blockbuster The year of the blockbuster

    Steglatro (ertugliflozin) from Pfizer and Merck:Sodium glucose co-transporter-2 (SGLT-2) inhibitors are the newest oral treatment options for diabetes, but SGLT-2 inhibitor Steglatro will be a late ... Steglatro has now been launched in the US and an EMA

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use in adults with type 2 ... Steglatro and Steglujan are

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • NICE – but not enough NICE – but not enough

    Steglatro launched as a new SGLT2 in early 2019 and was quickly bolstered by two NICE TAs. ... Armed with positive NICE guidance, MSD did a great job of getting Steglatro on formulary.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...